C12N 2750/00071
Demonstrated in vivo effect
C12N2750/00071 (Demonstrated in vivo effect) appears on 3 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 7
- Assignees
- 4
- Inventors
- 28
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 2 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anellovirus constructs comprising recombination sites and cross-packaging of anellovector particles and genetic elements3 Oct 2024US 2024/0327867 A1Flagship Pioneering Innovations V, Inc.
- Tandem anellovirus constructs2 Nov 2023US 2023/0348933 A1Flagship Pioneering Innovations V, Inc.
- Methods of identifying and characterizing anelloviruses and uses thereof20 Jul 2023US 2023/0227849 A1Flagship Pioneering Innovations V, Inc.
- Anellosomes and methods of use10 Feb 2022US 2022/0042042 A1Flagship Pioneering Innovations V, Inc.
- Glaucoma treatment27 Aug 2020US 2020/0268858 A1Icahn School of Medicine at Mount Sinai
Most cited
By later US patents